Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Recently, Immunofoco, a developer of immunocyte therapeutic drugs for solid tumors, has secured B+ round financing. The investors in this round are China Taiping Insurance Group Co., Ltd., Boru Capital, Soochow Investment Co., Ltd. (affiliated with Soochow Securities), and Guangdong Technology Financial Group Co., Ltd.Immunofoco, starting from the pain points of solid tumor treatment and clinical benefits, has proposed the clinical strategy of "transforming solid tumors into hematological tumors" for the first time globally. Based on this, it developed the Peri Cruiser® technology platform, as well as other technology platforms such as SNR and T-Booster, aiming to enhance the safety of CAR-T products, combat tumor heterogeneity, and improve the ability of expansion and tumor infiltration.
The company has always been oriented towards clinical value, with a rich product pipeline. Among them, IMC002 (CLDN18.2 CAR-T) received orphan drug designation (ODD) from the U.S. FDA in July 2022, and its IND application received dual approval from both China and the U.S. in April 2023; IMC001 (EpCAM CAR-T) received ODD from the U.S. FDA in August 2023, and its IND application received dual approval from both China and the U.S. in February 2024; IMC008 (SNR CAR-T) has rapidly advanced to the IIT clinical research stage and received two ODDs from the U.S. FDA in August 2023.Used to treat stomach cancer and pancreatic cancer respectively。Immunofoco was founded in July 2020, with its headquarters located in Suzhou, Jiangsu., is a company focused onTumor ImmunotherapyAn innovative biotechnology enterprise. The company focuses on developing the next generation of CAR-T cell therapy drugs, committed toSolid TumorTransformed into a curable hematological tumor, bringing long-term survival benefits to solid tumor patients globally. In 2024, the company was honored with the title of National Potential Unicorn Enterprise; in 2025, the company was awarded the title of Jiangsu Province Potential Unicorn Enterprise.References:
Official Website
Mastering CAR-T Therapy, Stem Cell Therapy, and Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
